Cell News and Research

RSS

Revolutionary self healing bandage that uses the patient's own cells

A revolutionary type of 'self healing' bandage that uses the patient's own cells is being developed. The technique has already been tried successfully on patients with diabetic ulcers and in the long-term could offer a more effective, quicker and cost efficient way of treating many types of slow-healing wounds such as pressure ulcers.

24 May 2004

Cystic Fibrosis Foundation Therapeutics awards $21 million to Vertex

Vertex Pharmaceuticals Incorporated has announced that it has expanded its drug discovery and development collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation.

24 May 2004

Research shows that treatment with nitric oxide after storage may dramatically improve the viability of transplanted livers

About 5,000 liver transplants are performed annually in the United States, and a key factor ensuring success is maintaining a healthy donor organ that can function effectively in the recipient. However, transplanted livers typically incur substantial damage when blood flow is restored to the organ after the transplant.

24 May 2004

Researchers have identified the first gene linked to the productivity of the stem cells that produce sperm in mammals

Researchers have identified the first gene linked to the productivity of the stem cells that produce sperm in mammals. The discovery was made by applying the latest laboratory methods to a strain of mice restored from embryos frozen since the early 70s.

23 May 2004

An antibiotic, Tigecycline produces 74 percent cure rate in cSSSI patients

An antibiotic, currently being tested in clinical trials, produced a 74 percent cure rate for hospitalized patients with possibly life-threatening, complicated skin and skin structure infections (cSSSI).

23 May 2004

Researchers have developed technology to precisely measure the sensitivity of nerve fibers that wire up the brain during development

Through use of this technology, they discovered that these fibers, or axons, possess an incredible sensitivity to molecular guidance cues that direct the axon's route to its desired destination in the brain. Their findings are described in the June issue of Nature Neuroscience.

23 May 2004

Combination therapy may be useful in humans with spinal cord injury

A combination therapy using transplanted cells plus two experimental drugs significantly improves function in paralyzed rats, a new study shows. The results suggest that a similar therapy may be useful in humans with spinal cord injury.

23 May 2004

Using gene therapy to fight rheumatoid arthritis

Guided by a similar principle, arthritis researchers at the University of Florida and Harvard University hope to use gene therapy to help joint cells pump out a harmless protein that parks in receptor sites, leaving a notorious inflammatory agent “circling the lot” and unable to cause pain, swelling and possible joint damage.

21 May 2004

Genome research sheds light on Bardet-Biedl syndrome

By comparing the genomes of an alga, a weed and humans, a team of researchers has identified a new gene behind Bardet-Biedl syndrome (BBS), a complex condition marked by learning disabilities, vision loss and obesity.

21 May 2004

Are we as crazy as mad cows?

When proteins in our body work properly, we can see, smell, consume and digest food, grow muscle and brain cells. But when these infinitely useful biological building blocks fail, the most pernicious diseases arise. Susan Lindquist has scrutinized the complex origami-like shapes of proteins and come to understand how structural mistakes can lead to a frightening class of neurodegenerative disorders, including “Mad Cow Disease.”

20 May 2004

Weekly cycles of once-daily anti-drugs could reduce cost of HIV treatment

In a small study conducted at the U.S. National Institutes of Health (NIH), researchers have shown that it may be feasible to treat HIV-infected patients with a simple, once-daily regimen of anti-HIV drugs given in pre-planned, 7-day-on, 7-day-off cycles. This approach is known formally as “short-cycle structured intermittent antiretroviral therapy” (SIT) or colloquially as the “7-7” approach.

20 May 2004

FDA finalizes new rule on donor eligibility for human tissues and cells

FDA today published a final rule establishing donor eligibility criteria for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps) to help prevent the transmission of communicable disease when these products are transplanted.

20 May 2004

Natural biological process by which yeast cells dismantle amyloid fibers

Amyloid fibers, those clumps of plaque-like proteins that clog up the brains of Alzheimer's patients, have perplexed scientists with their robust structures. In laboratory experiments, they are able to withstand extreme heat and cold and powerful detergents that cripple most other proteins.

20 May 2004

Protein that appears to play a key role in Alzheimer's disease

A protein that allows human cancer to resist multiple anticancer drugs also appears to play a key role in Alzheimer's disease, according to research conducted at Fox Chase Cancer Center. The protein, active in brain tissue, could be a target for new drugs to treat patients with Alzheimer's.

20 May 2004

Cell division can be halted in multiple ways, with implications for cancer

Brown University researchers have found that there are multiple independent ways to stop cell division, a phenomenon that prevents the spread of genetic mutation, which can make cells cancerous. Results of this research, along with an accompanying editorial, were published in the current issue of the journal Molecular Cell.

20 May 2004

Scientists have sped up a common jumping gene found in the human genome

Johns Hopkins scientists have transformed a common "jumping gene" found in the human genome into one that moves hundreds of times more often than normal in mouse and human cells.

20 May 2004

Patients with leukemia or lymphoma who undergo hematopoietic-cell transplantation and survive can expect full recovery to take 3-5 years

Patients with leukemia or lymphoma who undergo hematopoietic-cell transplantation (HCT) and survive can expect full recovery to take 3-5 years, according to a study published in the May 19 issue of The Journal of the American Medical Association (JAMA).

19 May 2004

New study of tumor genetics may help to treat patients with head and neck cancer

Head and neck tumors account for more than 40,000 new cancers annually in the United States. The most common of these is squamous cell carcinoma. Prognosis is based largely on location and size of the tumor, and if the cancer has spread, or metastasized, to lymph nodes and distant sites in the body.

19 May 2004

$First drug approved for hormone refractory prostate cancer that has shown a survival benefit$

First drug approved for hormone refractory prostate cancer that has shown a survival benefit

The the Food and Drug Administration (FDA) approved Taxotere (docetaxel), injection in combination with prednisone ( a steroid), for the treatment of patients with advanced metastatic prostate cancer. This is the first drug approved for hormone refractory prostate cancer that has shown a survival benefit.

19 May 2004

FDA approves new drug for bone marrow disease

The Food and Drug Administration (FDA) today announced the approval of Vidaza (azacitidine) injection, the first effective treatment for patients with Myelodysplastic Syndrome (MDS). The product was given Fast Track Status and a priority review.

19 May 2004